×
News Home

Where Does Puma Biotechnology Inc (PBYI) Stock Fall in the Biotechnology Field After It Is Lower By 0.00% This Week?

Friday, May 27, 2022 01:03 PM | InvestorsObserver Analysts
Where Does Puma Biotechnology Inc (PBYI) Stock Fall in the Biotechnology Field After It Is Lower By 0.00% This Week?

The 45 rating InvestorsObserver gives to Puma Biotechnology Inc (PBYI) stock puts it near the middle of the Biotechnology industry. In addition to scoring higher than 59 percent of stocks in the Biotechnology industry, PBYI’s 45 overall rating means the stock scores better than 45 percent of all stocks.

Overall Score - 45
PBYI has an Overall Score of 45. Find out what this means to you and get the rest of the rankings on PBYI!

What do These Ratings Mean?

Finding the best stocks can be tricky. It isn’t easy to compare companies across industries. Even companies that have relatively similar businesses can be tricky to compare sometimes. InvestorsObserver’s tools allow a top-down approach that lets you pick a metric, find the top sector and industry and then find the top stocks in that sector.
Our proprietary scoring system captures technical factors, fundamental analysis and the opinions of analysts on Wall Street. This makes InvestorsObserver’s overall rating a great way to get started, regardless of your investing style. Percentile-ranked scores are also easy to understand. A score of 100 is the top and a 0 is the bottom. There’s no need to try to remember what is “good” for a bunch of complicated ratios, just pay attention to which numbers are the highest.

What's Happening With Puma Biotechnology Inc Stock Today?

Puma Biotechnology Inc (PBYI) stock is trading at $2.00 as of 1:00 PM on Friday, May 27, an increase of $0.03, or 1.79% from the previous closing price of $1.96. The stock has traded between $1.92 and $2.03 so far today. Volume today is light. So far 91,293 shares have traded compared to average volume of 377,837 shares. Click Here to get the full Stock Report for Puma Biotechnology Inc stock.

You May Also Like

Get the InvestorsObserver App

InvestorsObserver App
iOS App Android App